scholarly journals The efficacy of the boric acid-based maintenance therapy in preventing recurrent vulvovaginal candidiasis

2021 ◽  
Vol 38 (4) ◽  
pp. 461-465
Author(s):  
Üzeyir KALKAN ◽  
Murat YASSA ◽  
Kemal SANDAL ◽  
Arzu Bilge TEKİN ◽  
Ceyhun KILINÇ ◽  
...  
Keyword(s):  
Boric Acid ◽  
Lifestyle Changes ◽  
Vulvovaginal Candidiasis ◽  
Antifungal Drugs ◽  
First Year ◽  
Recurrence Rates ◽  
Recurrent Vulvovaginal Candidiasis ◽  
Life Style Changes ◽  
Treatment Package ◽  
Vaginal Estriol

Current gold-standard treatment of recurrent vulvovaginal candidiasis (RVVC) is mainly based on maintenance with fluconazole. Moderate to high recurrence rates at long-term use and secondary fluconazole resistance emerge as reasons to seek for new topical maintenance regimens. In this study, it is aimed to assess the efficacy and safety of boric acid-based treatment approach to treat clinical RVVC. In this retrospective study, patients who were diagnosed with RVVC received a treatment package for six months that consist of induction with boric acid vaginal suppositories 600 mg daily for 14 nights followed by maintenance for five nights starting with every fifth day of the menstrual cycles; a vaginal estriol-lactobacilli combination; and several rigorous life-style changes. The success was defined as the absence of symptomatic recurrence during the follow-up. Success rate at the first year was found to be 94.8% in a total of 173 patients. Mild, reversible side effects were observed in five patients (2.9%). Boric acid, along with a vaginal estriol-lactobacilli combination and lifestyle changes can be a safe and effective alternative in lieu of potent systemic antifungal drugs as a first-line treatment for the patients referred with RVVC.

scholarly journals Cliniciansʼ Use of Intravaginal Boric Acid Maintenance Therapy for Recurrent Vulvovaginal Candidiasis and Bacterial Vaginosis

2019 ◽  
Vol 46 (12) ◽  
pp. 810-812
Author(s):  
Anna Powell ◽  
Khalil G. Ghanem ◽  
Linda Rogers ◽  
Ashley Zinalabedini ◽  
Rebecca M. Brotman ◽  
...  
Keyword(s):  
Maintenance Therapy ◽  
Boric Acid ◽  
Bacterial Vaginosis ◽  
Vulvovaginal Candidiasis ◽  
Recurrent Vulvovaginal Candidiasis

Boric Acid for Recurrent Vulvovaginal Candidiasis: The Clinical Evidence

2011 ◽  
Vol 20 (8) ◽  
pp. 1245-1255 ◽  
Author(s):  
Christos Iavazzo ◽  
Ioannis D. Gkegkes ◽  
Ioanna M. Zarkada ◽  
Matthew E. Falagas
Keyword(s):  
Boric Acid ◽  
Clinical Evidence ◽  
Vulvovaginal Candidiasis ◽  
Recurrent Vulvovaginal Candidiasis

scholarly journals Identification of etiologic agents of recurrent vulvovaginal candidiasis in patients from Isfahan, Iran

2020 ◽  
Vol 7 (2) ◽  
pp. e18-e18
Author(s):  
Kiana Shirani ◽  
Zahra Allameh ◽  
Azadeh Moshtzan
Keyword(s):  
Candida Albicans ◽  
Candida Glabrata ◽  
Vulvovaginal Candidiasis ◽  
Antifungal Drugs ◽  
Childbearing Age ◽  
Recurrent Vulvovaginal Candidiasis ◽  
Number Of Children ◽  
Common Pathogen ◽  
Etiologic Agents ◽  
Meaningful Relationship

Introduction: Occurrence of vulvovaginal candidiasis (VVC), as a common condition in women of childbearing age, is increasing all over the world as a result of extensive use of antibiotics and antifungal drugs. Objectives: In the present study to gain the up-to-date information on involved species and the prevalence of the recurrent vulvovaginal candidiasis (RVVC) in Isfahan, Iran, we assessed the etiologic agents of aforementioned disease in women referred to the Al-Zahra hospital (Isfahan, Iran). Furthermore, we surveyed the possible relationship between age, education and marital status with prevalence of albicans and non-albicans candidiasis. Patients and Methods: Our study was conducted on subjects who were admitted to the gynecology and midwifery clinic between September 2017 and August 2018 and had clinical presentations of vulvovaginitis. Sampling of 100 women was done using sterile swab. Samples were transferred to the hospital laboratory for cellular and molecular investigations. Results:Candida albicans was the main pathogen involved in the pathogenesis of RVVC and Candida glabrata is the second most common pathogen. Moreover, none of the 100 cases that we tested were infected with Candida krusei. We found a meaningful relationship between age and RVVC triggered by Candida albicans (P<0.05) but there was no significant relationship between age and RVVC that triggered by non-albicans fungi. There was no meaningful correlation between levels of education, number of children and types of delivery with RVVC that infected by various albicans and non-albicans candidiasis (P>0.05). Conclusion:Candidaalbicans was the main pathogen involved in the pathogenesis of RVVC in Isfahan while Candida glabrata is the second most common pathogen. Despite their high cost, molecular methods have high value in accurate diagnosis of the RVVC.

scholarly journals Vaginal isolates of Candida glabrata are Uniquely Susceptible to Killer Toxins Produced by Saccharomyces Yeasts

2020 ◽  
Author(s):  
Lance R. Fredericks ◽  
Mark D. Lee ◽  
Cooper R. Roslund ◽  
Mason A. Shipley ◽  
Paul A. Rowley
Keyword(s):  
Candida Glabrata ◽  
Vulvovaginal Candidiasis ◽  
Antifungal Drugs ◽  
Clinical Isolates ◽  
Pathogenic Species ◽  
Large Collection ◽  
Antifungal Activities ◽  
Recurrent Vulvovaginal Candidiasis ◽  
Killer Toxins ◽  
Saccharomyces Yeasts

ABSTRACTKiller toxins have a range of antifungal activities against pathogenic species of yeasts. Candida glabrata was found to be acutely susceptible to seven killer toxins produced by Saccharomyces species of yeasts. Specifically, the ionophoric K1 and K2 killer toxins were broadly inhibitory to a large collection of C. glabrata from patients with recurrent vulvovaginal candidiasis. The sensitivity of these clinical isolates to killer toxins does not correlate with their resistance to major classes of antifungal drugs.

scholarly journals Lactobacillus crispatus BC1 Biosurfactant Delivered by Hyalurosomes: An Advanced Strategy to Counteract Candida Biofilm

Antibiotics ◽  
2021 ◽  
Vol 10 (1) ◽  
pp. 33
Author(s):  
Angela Abruzzo ◽  
Barbara Giordani ◽  
Carola Parolin ◽  
Priscilla R. De Gregorio ◽  
Claudio Foschi ◽  
...  
Keyword(s):  
Storage Period ◽  
Vulvovaginal Candidiasis ◽  
Antifungal Drugs ◽  
Adhesive Properties ◽  
Lactobacillus Crispatus ◽  
Natural Substances ◽  
Candida Infections ◽  
Emergence Of Resistance ◽  
Potential Stability ◽  
Candida Biofilm

The emergence of resistance to antifungal drugs has made the treatment of vulvovaginal candidiasis (VVC) very challenging. Among natural substances, biosurfactants (BS) produced by Lactobacillus have gained increasing interest in counteracting Candida infections for their proven anti-adhesive properties and safety profile. In the present study, liposomes (LP-BS) or liposomes coated with hyaluronic acid (HY-LP-BS) were prepared in the presence of the BS isolated from the vaginal strain Lactobacillus crispatus BC1 and characterized in terms of size, ζ potential, stability and mucoadhesion. The anti-biofilm activity of free BS, LP-BS and HY-LP-BS was investigated against different Candida albicans and non-albicans strains (C. glabrata, C. lusitaniae, C. tropicalis, C. krusei and C. parapsilosis), clinically isolated from patients affected by VVC. The inhibition of biofilm formation and the dispersal of pre-formed biofilm were evaluated. The obtained phospholipid vesicles showed suitable size for vaginal application and good stability over the storage period. HY-LP-BS exhibited good mucoadhesive properties and the best anti-biofilm profile, both in preventing or limiting the surface colonization by a broad spectrum of Candida species. In conclusion, the formulation of a novel antifungal agent derived from the vaginal microbiota into mucoadhesive nanocarriers appears to be a promising biotherapeutic strategy to counteract vulvovaginal candidiasis.

Sign in / Sign up

Export Citation Format

Share Document